EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY-NC-ND 4.0

Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept

Maria Domenica Cappellini, Ali T Taher iD, Antonio Piga, Farrukh Shah, Ersi Voskaridou, Vip Viprakasit, John B Porter, Olivier Hermine, Ellis J Neufeld, Alexis A Thompson, Derek Tang, Aylin Yucel und 8 weitere

European Journal of Haematology · 2023

DOI: 10.1111/ejh.13975 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Maria Domenica Cappellini und 19 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy. Hauptthemen laut MEDLINE: beta-Thalassemia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol Myers Squibb, BMS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with transfusion‐dependent (TD) β‐thalassemia require long‐term red blood cell transfusions (RBCTs) that lead to iron overload, impacting health‐related quality of life (HRQoL).

Methods

The impact of luspatercept, a first‐in‐class erythroid maturation agent, versus placebo on HRQoL of patients with TD β‐thalassemia was evaluated in the phase 3 BELIEVE trial. HRQoL was assessed at baseline and every 12 weeks using the 36‐item Short Form Health Survey (SF‐36) and Transfusion‐dependent Quality of Life questionnaire (TranQol). Mean change in HRQoL was evaluated from baseline to week 48 for patients receiving luspatercept + best supportive care (BSC) and placebo + BSC and between luspatercept responders and non‐responders.

Results

Through week 48, for both groups, mean scores on SF‐36 and TranQol domains were stable over time and did not have a clinically meaningful change. At week 48, more patients who achieved clinical response (≥50% reduction in RBCT burden over 24 weeks) in the luspatercept + BSC group had improvement in SF‐36 Physical Function compared with placebo + BSC (27.1% vs. 11.5%; p = .019).

Conclusions

Luspatercept + BSC reduced transfusion burden while maintaining patients' HRQoL. HRQoL domain improvements from baseline through 48 weeks were also enhanced for luspatercept responders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-ThalassemiaHumansActivin Receptors, Type IIImmunoglobulin Fc FragmentsQuality of LifeRecombinant Fusion Proteins

Stichwörter der Autor:innen

beta-thalassemiairon overloadquality of life

Substanzen

Activin Receptors, Type IIImmunoglobulin Fc FragmentsluspaterceptRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
  • Department of Haematology, Whittington Health NHS Trust, London, UK.
  • Centre of Excellence in Rare Haematological Diseases-Haemoglobinopathies, Laiko General Hospital, Athens, Greece.
  • Siriraj Hospital, Mahidol University, Bangkok, Thailand.

ORCID-Profile: Ali T Taher

Förderung

  • Bristol Myers Squibb
  • BMS

Zitieren

APA

Cappellini, M. D., Taher, A. T., Piga, A., Shah, F., Voskaridou, E., Viprakasit, V., Porter, J. B., Hermine, O., Neufeld, E. J., Thompson, A. A., Tang, D., Yucel, A., Lord-Bessen, J., Yu, P., Guo, S., Shetty, J. K., Miteva, D., Zinger, T., Backstrom, J. T., & Oliva, E. N. (2023). Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept. European Journal of Haematology. https://doi.org/10.1111/ejh.13975

Vancouver

Cappellini MD, Taher AT, Piga A, Shah F, Voskaridou E, Viprakasit V, et al. Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept. European Journal of Haematology. 2023. doi:10.1111/ejh.13975

BibTeX
@article{Cappellini2023,
  author = {Cappellini, Maria Domenica and Taher, Ali T and Piga, Antonio and Shah, Farrukh and Voskaridou, Ersi and Viprakasit, Vip and Porter, John B and Hermine, Olivier and Neufeld, Ellis J and Thompson, Alexis A and Tang, Derek and Yucel, Aylin and Lord-Bessen, Jennifer and Yu, Peiwen and Guo, Shien and Shetty, Jeevan K and Miteva, Dimana and Zinger, Tatiana and Backstrom, Jay T and Oliva, Esther Natalie},
  title = {Health‐related quality of life in patients with β‐thalassemia: Data from the phase 3 BELIEVE trial of luspatercept},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.13975}
}
Kostenlos starten →